{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2017"],"data_sharing_plan":["IPD Sharing (as of March 2023): No"],"condition":["Ovarian Cancer","Melanoma","Colorectal Cancer","Advanced Solid Tumor","Neoplasms"],"disease":["Ovarian Cancer","Melanoma","Colorectal Cancer","Advanced Solid Tumor","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2250979"],"location":["United States"],"study_start_month":["8"],"keyword":["Pembrolizumab","Trebananib","Renal Cancer"],"repository":["ECRIN MDR"],"study_status":["Active, not recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor","description":"This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer.\nThe drugs involved in this study are:\n* Pembrolizumab\n* AMG386","dates":{"creation":"2017-08-15"},"accession":"2250979","cross_references":{"ClinicalTrials___gov":["NCT03239145"]}}